Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases

1. A benzsulfonamide according to formula I

its geometrical isomers, in an optically active form as enantiomers, diastereomers, racemates, or pharmaceutically acceptable salts thereof, wherein

Ar 1 is selected from the group consisting of an unsubstituted aryl group, an unsubstituted heteroaryl group, a substituted aryl group, and a substituted heteroaryl group;

R 1 is hydrogen or a C 1 -C 6 -alkyl group;

R 2 is hydrogen, —COOR 3 , —CONR 3 R 3′ , OH, a C 1 -C 4 alkyl substituted with an OH group, a hydrazido carbonyl group, a sulfate, a sulfonate, an amine or an ammonium salt;

n is either 0 or 1;

Y is a pyrrolidinyl group represented by the following formula:

whereby, L 1 is selected from the group consisting of C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 4 -C 8 -cycloalkyl optionally containing 1-3 heteroatoms and optionally fused with aryl or heteroaryl, aryl, heteroaryl, aryl-C 1 -C 6 -alkyl, heteroaryl-C 1 -C 6 -alkyl, —C(O)—OR 3 , —C(O)—R 3 , —C(O)—NR 3′ R 3 , —NR 3′ R 3 , —NR 3′ C(O)R 3 , —NR 3′ C(O)NR 3′ R 3 , —(SO)R 3 , —(SO 2 )R 3 , —NHSO 2 R 3 , and —SO 2 NR 3′ R 3 ,

with R 3 , R 3′ being substituents independently selected from the group consisting of H, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, aryl, heteroaryl, aryl-C 1 -C 6 -alkyl, and heteroaryl-C 1 -C 6 -alkyl; and

R 6 is selected from the group consisting of hydrogen, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, OH, halogen, nitro, cyano, sulfonyl, and oxo (═O), and

n′ is an integer from 0 to 4.

2. A benzsulfonamide according to claim 1 , wherein Ar 1 is selected from the group consisting of phenyl, thienyl, furyl, and pyridyl.

3. A benzsulfonamide according to claim 1 , wherein Ar 1 is a phenyl.

4. A benzsulfonamide according to claim 1 , wherein Ar 1 is selected from the group consisting of halogenophenyl, nitrophenyl, hydroxyphenyl, alkoxy phenyl, pyridyl, 3,4,-dihydroxyphenyl, thioxo-dihydropyridine or its tautomer, and pyrazole, R 1 is hydrogen, n is 1.

5. A benzsulfonamide selected from the group consisting of

4-chloro-N-(3-{[3-(hexylamino)-1-pyrrolidinyl]sulfonyl}phenyl)benzamide;

4-chloro-N-(3-{[3-({2-[3-(trifluoromethyl)phenyl]ethyl}amino)-1-pyrrolidinyl]sulfonyl}phenyl)benzamide;

4-chloro-N-{4-[(3-{[4-(trifluoromethyl)benzyl]amino}-1-pyrrolidinyl)sulfonyl]phenyl}benzamide;

4-chloro-N-(4-{[3-(hexylamino)-1-pyrrolidinyl]sulfonyl}phenyl)benzamide;

4-chloro-N-(4-{[3-({2-[3-(trifluoromethyl)phenyl]ethyl}amino)-1-pyrrolidinyl]sulfonyl}phenyl)benzamide; and

4-chloro-N-{3-[(3-{[4-(trifluoromethyl)benzyl]amino}-1-pyrrolidinyl)sulfonyl]benzyl}benzamide.

6. A method of treating a neuronal disorder, an auto-immune disease, a cancer, a cardiovascular disease, an ischemic condition or renal failure comprising administering an effective amount of a benzsulfonamide according to claim 1 to a subject in need thereof,

wherein said neuronal disorder is selected from the group consisting of epilepsy, Alzheimer's disease, Huntington's disease, Parkinson's disease, retinal diseases, spinal cord injury, Multiple Sclerosis, head trauma, and ischemia,

wherein said auto-immune disease is selected from the group consisting of inflammatory bowel disease (IBD), rheumatoid arthritis, asthma, septic shock, and transplant rejection,

wherein said cancer is selected from the group consisting of breast-cancer, colorectal-cancer, pancreatic cancer, ovarian cancer, prostate cancer, testicular cancer, hepatic cancer, kidney cancer, and lung cancer,

wherein said cardiovascular disease is selected from the group consisting of stroke, arterosclerosis, myocardial infarction, and myocardial reperfusion injury, and

wherein said ischemic condition is selected from the group consisting of heart reperfusion injury, renal reperfusion injury, kidney reperfusion injury, and brain reperfusion injury.

7. A pharmaceutical composition containing a benzsulfonamide according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

8. A process for the preparation of a benzsulfonamide according to claim 1 , wherein a sulfonamide (XIX)

wherein Ar 1 , R 1 , R 2 and n are as defined in claim 1 and Y is a pyrrolidine-3-one,

is subjected to a reductive amination using an amine H 2 N—R 3 with R 3 as defined in claim 1 .

9. A process according to claim 8 , wherein the following steps are performed:

10. A sulfonamide compound of formula (XIX)

wherein

Ar 1 is an aryl or heteroaryl group;

R 1 is hydrogen or a C 1 -C 6 -alkyl group;

R 2 is hydrogen, —COOR 3 , —CONR 3 R 3′ , OH, a C 1 -C 4 alkyl substituted with an OH group, a hydrazido carbonyl group, a sulfate, a sulfonate, an amine or an ammonium salt;

R 3 and R 3′ are independently selected from the group consisting of H, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, aryl, heteroaryl, aryl-C 1 -C 6 -alkyl, and heteroaryl-C 1 -C 6 -alkyl;

n is either 0 or 1, and

Y is a pyrrolidine-3-one, or a salt thereof.